open access

Vol 53, No 1 (2015)
ORIGINAL PAPERS
Published online: 2015-04-14
Submitted: 2015-03-18
Accepted: 2015-03-20
Get Citation

The alterations in SATB1 and nuclear F-actin expression affect apoptotic response of the MCF-7 cells to geldanamycin

Dariusz Grzanka, Magdalena Izdebska, Anna Klimaszewska-Wisniewska, Maciej Gagat
DOI: 10.5603/FHC.a2015.0008
·
Pubmed: 25809470
·
Folia Histochem Cytobiol 2015;53(1):79-87.

open access

Vol 53, No 1 (2015)
ORIGINAL PAPERS
Published online: 2015-04-14
Submitted: 2015-03-18
Accepted: 2015-03-20

Abstract

Introduction. The function and localization of actin in the nucleus have not yet been fully described. However, actin seems to be a key protein in nuclear processes interacting with chromatin and matrix proteins. The aim of the study was to evaluate the effect of controlled expression of nuclear pool of F-actin and special AT-rich sequence-binding protein 1 (SATB1) on the in vitro induction of active cell death by geldanamycin (GA).

Material and methods. The expression of SATB1 was regulated by the transfection of non-aggressive breast cancer MCF-7 cells with siRNA against SATB1 or expression plasmid with cloned cDNA of SATB1. The altered expression of cofilin-1 in these cells was used to regulate the nuclear expression and localization of F-actin. The effect of GA was analyzed in the context of cell death induction and cell cycle alterations.

Results. Our studies revealed that the targeted regulation of SATB1 and cofilin-1 expression changed the apoptotic response of the MCF-7 cells to GA. The overexpression of these proteins potentiated GA-induced arrest of the cells in the G1 phase of cell cycle and increased the population of the hypodiploid cells.

Conclusion. The alterations in the nuclear expression of SATB1 and F-actin in MCF-7 cells may affect their active cell death in response to GA.

Abstract

Introduction. The function and localization of actin in the nucleus have not yet been fully described. However, actin seems to be a key protein in nuclear processes interacting with chromatin and matrix proteins. The aim of the study was to evaluate the effect of controlled expression of nuclear pool of F-actin and special AT-rich sequence-binding protein 1 (SATB1) on the in vitro induction of active cell death by geldanamycin (GA).

Material and methods. The expression of SATB1 was regulated by the transfection of non-aggressive breast cancer MCF-7 cells with siRNA against SATB1 or expression plasmid with cloned cDNA of SATB1. The altered expression of cofilin-1 in these cells was used to regulate the nuclear expression and localization of F-actin. The effect of GA was analyzed in the context of cell death induction and cell cycle alterations.

Results. Our studies revealed that the targeted regulation of SATB1 and cofilin-1 expression changed the apoptotic response of the MCF-7 cells to GA. The overexpression of these proteins potentiated GA-induced arrest of the cells in the G1 phase of cell cycle and increased the population of the hypodiploid cells.

Conclusion. The alterations in the nuclear expression of SATB1 and F-actin in MCF-7 cells may affect their active cell death in response to GA.

Get Citation

Keywords

SATB1; F-actin; cofilin-1; geldanamycin; apoptosis; MCF-7 cells; siRNA; transfection

About this article
Title

The alterations in SATB1 and nuclear F-actin expression affect apoptotic response of the MCF-7 cells to geldanamycin

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 53, No 1 (2015)

Pages

79-87

Published online

2015-04-14

DOI

10.5603/FHC.a2015.0008

Pubmed

25809470

Bibliographic record

Folia Histochem Cytobiol 2015;53(1):79-87.

Keywords

SATB1
F-actin
cofilin-1
geldanamycin
apoptosis
MCF-7 cells
siRNA
transfection

Authors

Dariusz Grzanka
Magdalena Izdebska
Anna Klimaszewska-Wisniewska
Maciej Gagat

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl